✦ LIBER ✦

Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients

✍ Scribed by Murray B. Stein; Carol Kerridge; Joel E. Dimsdale; David B. Hoyt

Publisher: Springer
Year: 2007
Tongue: English
Weight: 154 KB
Volume: 20
Category: Article
ISSN: 0894-9867
DOI: 10.1002/jts.20270

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Acute physical injury is frequently associated with mental health sequelae, which then accentuate disability and worsen functional outcomes. A pharmacological prevention approach to this problem has been proposed. This proof‐of‐concept study was a double‐blind, randomized controlled trial of 14 days of the beta‐blocker propranolol (n = 17), the anxiolytic anticonvulsant gabapentin (n = 14), or placebo (n = 17), administered within 48 hours of injury to patients admitted to a surgical trauma center. Of 569 accessible, potentially eligible subjects, 48 (8%) participated. Outcomes assessments were conducted at 1, 4, and 8 months postinjury. Although well tolerated, neither study drug showed a significant benefit over placebo on depressive or posttraumatic stress symptoms. Implications are discussed for future pharmacological prevention studies in survivors of acute traumatic injury.

📜 SIMILAR VOLUMES

Cabergoline compared to levodopa in the

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial

✍ Claudia Trenkwalder; Heike Benes; Ludger Grote; Svenja Happe; Birgit Högl; Johan 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

## Abstract We report the first large‐scale double‐blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated with fixed daily dos

Impact of a tailored patient preference

Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: Results from an exploratory randomized controlled trial

✍ Tetyana Moshkovska; Margaret A. Stone; Roger M. Smith; John Bankart; Richard Bak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

Tocilizumab inhibits structural joint da

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year

✍ Joel M. Kremer; Ricardo Blanco; Marek Brzosko; Ruben Burgos-Vargas; Anne-Marie H 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB 👁 3 views